1/11/10 Since 1998, eight biologic response modifiers, known as biologics, have been approved by the Food and Drug Administration for inflammatory forms of arthritis. Biologics are genetically engineered medications made from living organisms that are then used to treat humans. Two biologics were approved in 2009, and several more are in various stages of development and clinical testing. Some of these agents that hold promise as future arthritis treatments include:
• Baminnercept (BG9924), an agent in development for rheumatoid arthritis (RA) and lupus, which targets lymphotoxin-beta, a component on the surface of cells that signals the inflammatory process to begin.
• Denosumab (AMG 162), which targets RANK ligand, a protein involved in the development of bony erosions in RA and bone loss in osteoporosis.
• Ofatumumab (HuMax-CD20), an infused biologic designed to reduce the number of B cells, which may decrease disease activity in RA
• Belimumab (Benlysta), which inhibits the activity of B-lymphocyte stimulator (BLys), a protein that causes B cells to grow in number and perhaps produce antibodies. Belimumab is in development for lupus as well as RA.
• Canakinumab (Ilaris), which targets the proinflammatory cytokine interleukin-1 beta (IL-1β). Approved for a rare autoimmune disorder called cryopyrin-associated periodic syndrome (CAPS), canakinumab is currently in clinical trials for RA and JIA.
• Fostamatinib disodium, an agent that works by blocking the effects of a protein called syk kinase, which helps B-cells to mature. Fostamatinib disodium is in clinical trials for RA.
• Masitinib, which inhibits the activity of mast cells, which become activated and contribute to joint inflammation in RA. Masitinib is taken orally and has been in clinical trials for RA.


























